Safety & Side Effects

What we know, what we do not, and the cancer question

Short-term, thymosin beta-4 looks reasonably well tolerated in trials: the intravenous phase 1 studies reported no dose-limiting toxicities and no serious adverse events, and in the two topical chronic-wound trials serious adverse events occurred at similar rates on drug and placebo. The serious, unresolved issue is its relationship with cancer: overexpression of the gene has been reported in many human carcinomas and linked to more aggressive tumor-cell behavior, yet in multiple myeloma lower expression tracked with worse outcomes, and in a mouse model the added protein suppressed a lung cancer. The evidence is mostly correlational, not settled.

This unit separates the reassuring short-term data from the genuine long-term gaps, walks the nuanced cancer picture in both directions, and lays out who should be most cautious.